157 related articles for article (PubMed ID: 29371000)
1. Pasireotide in acromegaly by aggressive tumors, description of four clinical cases. Towards a personalized medicine.
Biagetti B; Obiols G; Martinez Saez E; Cordero E; Mesa J
Endocrinol Diabetes Nutr (Engl Ed); 2018 Feb; 65(2):130-132. PubMed ID: 29371000
[No Abstract] [Full Text] [Related]
2. Pasireotide and Pegvisomant Combination Treatment in Acromegaly Resistant to Second-Line Therapies: A Longitudinal Study.
Chiloiro S; Bima C; Tartaglione T; Giampietro A; Gessi M; Lauretti L; Anile C; Colosimo C; Rindi G; Pontecorvi A; De Marinis L; Bianchi A
J Clin Endocrinol Metab; 2019 Nov; 104(11):5478-5482. PubMed ID: 31219586
[TBL] [Abstract][Full Text] [Related]
3. Long-term efficacy and safety of subcutaneous pasireotide in acromegaly: results from an open-ended, multicenter, Phase II extension study.
Petersenn S; Farrall AJ; De Block C; Melmed S; Schopohl J; Caron P; Cuneo R; Kleinberg D; Colao A; Ruffin M; Hermosillo Reséndiz K; Hughes G; Hu K; Barkan A
Pituitary; 2014 Apr; 17(2):132-40. PubMed ID: 23529827
[TBL] [Abstract][Full Text] [Related]
4. Potential antitumour activity of pasireotide on pituitary tumours in acromegaly.
Coopmans EC; van der Lely AJ; Schneiders JJ; Neggers SJCMM
Lancet Diabetes Endocrinol; 2019 Jun; 7(6):425-426. PubMed ID: 30956093
[No Abstract] [Full Text] [Related]
5. Acromegaly can be cured by first-line pasireotide treatment?
Chiloiro S; Giampietro A; Bianchi A; Tartaglione T; Bima C; Vita MG; Spinello M; Pontecorvi A; De Marinis L
Endocrine; 2019 Apr; 64(1):196-199. PubMed ID: 30798431
[No Abstract] [Full Text] [Related]
6. Presurgical treatment with somatostatin analogs in patients with acromegaly: effects on the remission and complication rates.
Losa M; Mortini P; Urbaz L; Ribotto P; Castrignanó T; Giovanelli M
J Neurosurg; 2006 Jun; 104(6):899-906. PubMed ID: 16776333
[TBL] [Abstract][Full Text] [Related]
7. Predicting the effects of long-term medical treatment in acromegaly. At what cost? For what benefits?
Chanson P
Eur J Endocrinol; 1997 Apr; 136(4):359-61. PubMed ID: 9150692
[No Abstract] [Full Text] [Related]
8. [Outcome of somatostatin analogue treatment in acromegaly].
Mondok A; Tóth M; Patócs A; Szücs N; Igaz P; Pusztai P; Czirják S; Beko G; Gláz E; Rácz K; Tulassay Z
Orv Hetil; 2009 Aug; 150(31):1457-62. PubMed ID: 19617182
[TBL] [Abstract][Full Text] [Related]
9. Efficacy and safety of long-acting pasireotide in patients with somatostatin-resistant acromegaly: a multicenter study.
Shimon I; Adnan Z; Gorshtein A; Baraf L; Saba Khazen N; Gershinsky M; Pauker Y; Abid A; Niven MJ; Shechner C; Greenman Y
Endocrine; 2018 Nov; 62(2):448-455. PubMed ID: 30051198
[TBL] [Abstract][Full Text] [Related]
10. Long-term treatment of acromegaly with the somatostatin analogue SR-lanreotide.
Suliman M; Jenkins R; Ross R; Powell T; Battersby R; Cullen DR
J Endocrinol Invest; 1999 Jun; 22(6):409-18. PubMed ID: 10435849
[TBL] [Abstract][Full Text] [Related]
11. Switching patients with acromegaly from octreotide to pasireotide improves biochemical control: crossover extension to a randomized, double-blind, Phase III study.
Bronstein MD; Fleseriu M; Neggers S; Colao A; Sheppard M; Gu F; Shen CC; Gadelha M; Farrall AJ; Hermosillo Reséndiz K; Ruffin M; Chen Y; Freda P;
BMC Endocr Disord; 2016 Apr; 16():16. PubMed ID: 27039081
[TBL] [Abstract][Full Text] [Related]
12. Impact of preoperative pasireotide therapy on invasive octreotide-resistant acromegaly.
Yamamoto R; Robert Shima K; Igawa H; Kaikoi Y; Sasagawa Y; Hayashi Y; Inoshita N; Fukuoka H; Takahashi Y; Takamura T
Endocr J; 2018 Oct; 65(10):1061-1067. PubMed ID: 30078825
[TBL] [Abstract][Full Text] [Related]
13. Another case where bigger is not better.
Weber KT
Cardiovasc Res; 1997 Oct; 36(1):1-2. PubMed ID: 9415265
[No Abstract] [Full Text] [Related]
14. Surgical debulking of pituitary macroadenomas causing acromegaly improves control by lanreotide.
Karavitaki N; Turner HE; Adams CB; Cudlip S; Byrne JV; Fazal-Sanderson V; Rowlers S; Trainer PJ; Wass JA
Clin Endocrinol (Oxf); 2008 Jun; 68(6):970-5. PubMed ID: 18031313
[TBL] [Abstract][Full Text] [Related]
15. Pituitary gangliocytoma-adenoma presenting with acromegaly: response to treatment.
Luna V; Morales F; Luengo LM; Sanz A; Diaz J
Arch Intern Med; 2001 Apr; 161(7):1010-1. PubMed ID: 11295968
[No Abstract] [Full Text] [Related]
16. Serial follow-up of presurgical treatment using pasireotide long-acting release with or without octreotide long-acting release for naïve active acromegaly.
Chang JS; Tseng HM; Chang TC
J Formos Med Assoc; 2016 Jun; 115(6):475-80. PubMed ID: 27117887
[TBL] [Abstract][Full Text] [Related]
17. Pasireotide (SOM230) demonstrates efficacy and safety in patients with acromegaly: a randomized, multicenter, phase II trial.
Petersenn S; Schopohl J; Barkan A; Mohideen P; Colao A; Abs R; Buchelt A; Ho YY; Hu K; Farrall AJ; Melmed S; Biller BM;
J Clin Endocrinol Metab; 2010 Jun; 95(6):2781-9. PubMed ID: 20410233
[TBL] [Abstract][Full Text] [Related]
18. The effects of somatostatin analogue therapy on pituitary tumor volume in patients with acromegaly.
Colao A; Auriemma RS; Pivonello R
Pituitary; 2016 Apr; 19(2):210-21. PubMed ID: 26290466
[TBL] [Abstract][Full Text] [Related]
19. Somatostatin analogs in acromegaly.
Freda PU
J Clin Endocrinol Metab; 2002 Jul; 87(7):3013-8. PubMed ID: 12107192
[No Abstract] [Full Text] [Related]
20. [Novel pharmacologic therapies in acromegaly].
Góth M; Hubina E; Kovács L; Szabolcs I
Orv Hetil; 2002 May; 143(19 Suppl):1057-62. PubMed ID: 12063860
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]